{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:52:08Z","timestamp":1791384728469,"version":"4.3.3"},"reference-count":33,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Huntington's Disease"],"published-print":{"date-parts":[[2023,7,15]]},"abstract":"<jats:p>In this edition of the Huntington\u2019s Disease Clinical Trials Corner, we expand on the GENERATION HD2 (tominersen) and on the Asklepios Biopharmaceutical\/BrainVectis trial with AB-1001. We also comment on the recent findings from the PROOF-HD trial, and list all currently registered and ongoing clinical trials in Huntington\u2019s disease.<\/jats:p>","DOI":"10.3233\/jhd-239001","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T12:19:00Z","timestamp":1689682740000},"page":"169-185","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":39,"title":["Huntington\u2019s Disease Clinical Trials Corner: August 2023"],"prefix":"10.1177","volume":"12","author":[{"given":"Carlos","family":"Estevez-Fraga","sequence":"first","affiliation":[{"name":"Huntington\u2019s Disease Centre, UCL Queen Square Institute of Neurology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Tabrizi","sequence":"additional","affiliation":[{"name":"Huntington\u2019s Disease Centre, UCL Queen Square Institute of Neurology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Wild","sequence":"additional","affiliation":[{"name":"Huntington\u2019s Disease Centre, UCL Queen Square Institute of Neurology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,7,15]]},"reference":[{"key":"ref001","unstructured":"Hoffmann-LaRocheA Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington\u2019s Disease. 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05686551."},{"key":"ref002","unstructured":"Asklepios BioPharmaceutical. A Study to Evaluate AB-Striatal Administration in Adults With Early Manifest Huntington\u2019s Disease. 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05541627."},{"key":"ref003","unstructured":"Prilenia. PRidopidine\u2019s Outcome On Function in Huntington Disease, PROOF-HD. 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04556656."},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-170262"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00120-X"},{"key":"ref006","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004743"},{"key":"ref007","unstructured":"McColganPA phase II dose-finding study of tominersen. European Huntington\u2019s Disease Network Plenary Meeting. 2022. https:\/\/ehdn.org\/ehdn2022-day3\/."},{"key":"ref008","unstructured":"Ionis Pharmaceuticals. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-HTTRx in Patients With Early Manifest Huntington\u2019s Disease. 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02519036."},{"key":"ref009","unstructured":"Hoffman-LaRocheA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO292 (ISIS 39) in Huntington\u2019s Disease Patients Who Participated in Prior Investigational Studies of RO292 (ISIS 39). 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03342053."},{"key":"ref010","unstructured":"Hoffman-LaRocheA Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO292 (RGin Patients With Manifest Huntington\u2019s Disease. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03761849."},{"key":"ref011","author":"Boak L","year":"2022","journal-title":"CHDI Foundation Annual Therapeutics Conference 28tth February\u2013 3rd March"},{"key":"ref012","unstructured":"Asklepios BioPharmaceuticalBrainVectis, a subsidiary of AskBio, receives clearance to conduct Phase I\/II clinical trial in France for its novel gene therapy for early-stage Huntington\u2019s Disease. 2022. https:\/\/www.askbio.com\/brainvectis-a-subsidiary-of-askbio-receives-clearance-to-conduct-phase-i-ii-clinical-trial-in-france-for-its-novel-gene-therapy-for-early-stage-huntingtons-disease\/."},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2011.132"},{"key":"ref014","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.48.30178"},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv384"},{"key":"ref016","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz174"},{"key":"ref017","author":"Cartier-Lacave N","year":"2022","journal-title":"European Huntington\u2019s Disease Network Plenary Meeting"},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01022-9"},{"key":"ref019","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.705575"},{"key":"ref020","unstructured":"Teva Branded Pharmaceutical Products R&D Inc. A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington\u2019s Disease (HART). 2016. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT00724048."},{"key":"ref021","unstructured":"Prilenia. Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease (OPEN-HART). 2022. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01306929."},{"key":"ref022","unstructured":"Teva Branded Pharmaceutical Products R&D Inc. A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington\u2019s Disease (MermaiHD). 2016. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT00665223."},{"key":"ref023","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70233-2"},{"key":"ref024","unstructured":"PrileniaA Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington\u2019s Disease. 2021. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02006472."},{"key":"ref025","unstructured":"Prilenia.  A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington\u2019s Disease (Open PRIDE-HD). 2021. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02494778."},{"key":"ref026","unstructured":"Prilenia.  Prilenia Shares Preliminary Topline Results from Phase 3 PROOF-HD Clinical Trial in Huntington\u2019s Disease and Data from Phase 2 HEALEY ALS Platform Trial of Pridopidine at the 75th American Academy of Neurology (AAN) Annual Meeting. 2023. https:\/\/news.prilenia.com\/press-releases\/press-release-details\/2023\/Prilenia-Shares-Preliminary-Topline-Results-from-Phase-3-PROOF-HD-Clinical-Trial-in-Huntingtons-Disease-and-Data-from-Phase-2-HEALEY-ALS-Platform-Trial-of-Pridopidine-at-the-75th-American-Academy-of-Neurology-AAN-Annual-Meeting\/default.aspx."},{"key":"ref027","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-189001"},{"key":"ref028","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-189003"},{"key":"ref029","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-190001"},{"key":"ref030","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-199003"},{"key":"ref031","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-200002"},{"key":"ref032","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-229002"},{"key":"ref033","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-229006"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JHD-239001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JHD-239001","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JHD-239001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:56:16Z","timestamp":1777452976000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JHD-239001"}},"subtitle":[],"editor":[{"given":"Jenny","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,15]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,7,15]]}},"alternative-id":["10.3233\/JHD-239001"],"URL":"https:\/\/doi.org\/10.3233\/jhd-239001","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,15]]}}}